Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 1, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Developing imaging strategies for castration resistant prostate cancer.

Josef J Fox1, Michael J Morris, Steven M Larson

  • 1Nuclear Medicine Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. foxj@mskcc.org

Acta Oncologica (Stockholm, Sweden)
|May 25, 2011
PubMed
Summary

Developing molecular imaging biomarkers is crucial for evaluating new therapies targeting androgen-receptor (AR) signaling in castrate-resistant prostate cancer (CRPC). These biomarkers help determine treatment efficacy and guide drug selection for improved patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<sup>68</sup>Ga-PSMA PET/CT in biochemically recurrent prostate cancer: association with genomic data.

European journal of nuclear medicine and molecular imaging·2026
Same author

Functional Renal Assessment via Dynamic LAFOV <sup>18</sup>F-FDG PET/CT in a Patient with Recurrent Extranodal Marginal-Zone Lymphoma.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.

Transplantation and cellular therapy·2026
Same author

Nonsteroidal <sup>18</sup>F-Labeled PET Tracer for Imaging Androgen Receptors.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Diagnostic Value of Routine Delayed Pelvic Imaging for Patients with Biochemical Recurrence of Prostate Cancer Undergoing <sup>68</sup>Ga-PSMA PET/CT.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Outcomes of Salvage Therapy after Early-Line CD19 Chimeric Antigen Receptor T-Cell Failure in Large B-Cell Lymphoma.

Transplantation and cellular therapy·2026

Area of Science:

  • Oncology
  • Molecular Imaging
  • Biomarker Development

Background:

  • Castrate-resistant prostate cancer (CRPC) treatment is advancing with novel therapies targeting the androgen-receptor (AR) signaling axis.
  • Reliable molecular imaging biomarkers are needed to assess treatment efficacy and guide drug selection for these therapies.

Purpose of the Study:

  • To discuss the systematic development of molecular imaging biomarkers for CRPC.
  • To focus on bone scintigraphy, F-18 fluorodeoxyglucose (FDG)-positron emission tomography (PET), and AR signaling axis PET imaging.

Main Methods:

  • Review of current literature and expert experience in imaging biomarker development for CRPC.
  • Discussion of established criteria (e.g., PCWG2) and emerging PET tracers for AR signaling axis evaluation.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Related Experiment Videos

Last Updated: Jun 1, 2026

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Main Results:

  • Rigorous standardization and analytic validation are essential for biomarker development and clinical qualification.
  • While bone scintigraphy and FDG-PET have roles, their application in CRPC requires further evaluation. Novel PET tracers targeting the AR signaling axis are under development.

Conclusions:

  • Molecular imaging, especially targeting the AR signaling axis, can accelerate CRPC drug development.
  • Analytically valid imaging biomarkers are key to clinical qualification and improving patient outcomes in CRPC treatment.